204 related articles for article (PubMed ID: 31771391)
1. Current status of GPR40/FFAR1 modulators in medicinal chemistry (2016-2019): a patent review.
Li Z; Zhou Z; Zhang L
Expert Opin Ther Pat; 2020 Jan; 30(1):27-38. PubMed ID: 31771391
[No Abstract] [Full Text] [Related]
2. Recent Updates on Free Fatty Acid Receptor 1 (GPR-40) Agonists for the Treatment of Type 2 Diabetes Mellitus.
Rani L; Grewal AS; Sharma N; Singh S
Mini Rev Med Chem; 2021; 21(4):426-470. PubMed ID: 33100202
[TBL] [Abstract][Full Text] [Related]
3. A novel antidiabetic drug, fasiglifam/TAK-875, acts as an ago-allosteric modulator of FFAR1.
Yabuki C; Komatsu H; Tsujihata Y; Maeda R; Ito R; Matsuda-Nagasumi K; Sakuma K; Miyawaki K; Kikuchi N; Takeuchi K; Habata Y; Mori M
PLoS One; 2013; 8(10):e76280. PubMed ID: 24130766
[TBL] [Abstract][Full Text] [Related]
4. An updated patent review of GPR40/ FFAR1 modulators (2020 - present).
Ren Q; Fan Y; Yang L; Shan M; Shi W; Qian H
Expert Opin Ther Pat; 2023; 33(9):565-577. PubMed ID: 37947382
[TBL] [Abstract][Full Text] [Related]
5. GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus: Benefits and Challenges.
Mohammad S
Curr Drug Targets; 2016; 17(11):1292-300. PubMed ID: 26648068
[TBL] [Abstract][Full Text] [Related]
6. Free fatty acid receptor 1: a ray of hope in the therapy of type 2 diabetes mellitus.
Arora A; Behl T; Sehgal A; Singh S; Sharma N; Chigurupati S; Kaur R; Bhatia S; Al-Harrasi A; Vargas-De-La-Cruz C; Bungau S
Inflammopharmacology; 2021 Dec; 29(6):1625-1639. PubMed ID: 34669065
[TBL] [Abstract][Full Text] [Related]
7. Free Fatty Acid Receptor 1 (FFAR1) as an Emerging Therapeutic Target for Type 2 Diabetes Mellitus: Recent Progress and Prevailing Challenges.
Li Z; Xu X; Huang W; Qian H
Med Res Rev; 2018 Mar; 38(2):381-425. PubMed ID: 28328012
[TBL] [Abstract][Full Text] [Related]
8. FFAR1/GPR40: One target, different binding sites, many agonists, no drugs, but a continuous and unprofitable tug-of-war between ligand lipophilicity, activity, and toxicity.
Governa P; Caroleo MC; Carullo G; Aiello F; Cione E; Manetti F
Bioorg Med Chem Lett; 2021 Jun; 41():127969. PubMed ID: 33771587
[TBL] [Abstract][Full Text] [Related]
9. Synthetic GPR40/FFAR1 agonists: An exhaustive survey on the most recent chemical classes and their structure-activity relationships.
Paul A; Nahar S; Nahata P; Sarkar A; Maji A; Samanta A; Karmakar S; Maity TK
Eur J Med Chem; 2024 Jan; 264():115990. PubMed ID: 38039791
[TBL] [Abstract][Full Text] [Related]
10. Discovery of Potent and Orally Bioavailable GPR40 Full Agonists Bearing Thiophen-2-ylpropanoic Acid Scaffold.
Li H; Huang Q; Chen C; Xu B; Wang HY; Long YQ
J Med Chem; 2017 Apr; 60(7):2697-2717. PubMed ID: 28277660
[TBL] [Abstract][Full Text] [Related]
11. TAK-875, a GPR40/FFAR1 agonist, in combination with metformin prevents progression of diabetes and β-cell dysfunction in Zucker diabetic fatty rats.
Ito R; Tsujihata Y; Matsuda-Nagasumi K; Mori I; Negoro N; Takeuchi K
Br J Pharmacol; 2013 Oct; 170(3):568-80. PubMed ID: 23848179
[TBL] [Abstract][Full Text] [Related]
12. GPR40 agonists for the treatment of type 2 diabetes mellitus: The biological characteristics and the chemical space.
Chen C; Li H; Long YQ
Bioorg Med Chem Lett; 2016 Dec; 26(23):5603-5612. PubMed ID: 27825762
[TBL] [Abstract][Full Text] [Related]
13. Activation of GPR40 as a therapeutic target for the treatment of type 2 diabetes.
Burant CF
Diabetes Care; 2013 Aug; 36 Suppl 2(Suppl 2):S175-9. PubMed ID: 23882043
[TBL] [Abstract][Full Text] [Related]
14. GPR40-Mediated G
Rives ML; Rady B; Swanson N; Zhao S; Qi J; Arnoult E; Bakaj I; Mancini A; Breton B; Lee SP; Player MR; Pocai A
Mol Pharmacol; 2018 Jun; 93(6):581-591. PubMed ID: 29572336
[TBL] [Abstract][Full Text] [Related]
15. GPR40: a therapeutic target for mediating insulin secretion (review).
Feng XT; Leng J; Xie Z; Li SL; Zhao W; Tang QL
Int J Mol Med; 2012 Dec; 30(6):1261-6. PubMed ID: 23023155
[TBL] [Abstract][Full Text] [Related]
16. CPL207280, a Novel G Protein-Coupled Receptor 40/Free Fatty Acid Receptor 1-Specific Agonist, Shows a Favorable Safety Profile and Exerts Antidiabetic Effects in Type 2 Diabetic Animals.
Bazydlo-Guzenda K; Buda P; Matloka M; Mach M; Stelmach F; Dzida R; Smuga D; Hucz-Kalitowska J; Teska-Kaminska M; Vialichka V; Dubiel K; Kaminska B; Wieczorek M; Pieczykolan J
Mol Pharmacol; 2021 Oct; 100(4):335-347. PubMed ID: 34349026
[TBL] [Abstract][Full Text] [Related]
17. TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats.
Tsujihata Y; Ito R; Suzuki M; Harada A; Negoro N; Yasuma T; Momose Y; Takeuchi K
J Pharmacol Exp Ther; 2011 Oct; 339(1):228-37. PubMed ID: 21752941
[TBL] [Abstract][Full Text] [Related]
18. GPR120 agonists for the treatment of diabetes: a patent review (2014 present).
Zhang X; Macielag MJ
Expert Opin Ther Pat; 2020 Oct; 30(10):729-742. PubMed ID: 32799609
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and Characterization of a Promising Novel FFAR1/GPR40 Targeting Fluorescent Probe for β-Cell Imaging.
Bertrand R; Wolf A; Ivashchenko Y; Löhn M; Schäfer M; Brönstrup M; Gotthardt M; Derdau V; Plettenburg O
ACS Chem Biol; 2016 Jun; 11(6):1745-54. PubMed ID: 27115176
[TBL] [Abstract][Full Text] [Related]
20. GPR119 agonists for the treatment of type 2 diabetes: an updated patent review (2014-present).
Li H; Fang Y; Guo S; Yang Z
Expert Opin Ther Pat; 2021 Sep; 31(9):795-808. PubMed ID: 33896337
[No Abstract] [Full Text] [Related]
[Next] [New Search]